Clinical Trial Detail

NCT ID NCT02712723
Title Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Qamar Khan
Indications

Her2-receptor negative breast cancer

Therapies

Letrozole + Ribociclib

Age Groups: adult

Additional content available in CKB BOOST